Humira adalimumab: Phase III data

Data from Period A of the double-blind, international Phase III PIONEER I trial in 307 patients with moderate to severe hidradenitis suppurativa showed that subcutaneous Humira given at 160 mg at week 0, 80 mg at week 2 and then 40 mg

Read the full 428 word article

How to gain access

Continue reading with a
two-week free trial.